Rheumatoid Arthritis
A chronic autoimmune disease causing joint inflammation, pain, stiffness, and progressive joint damage. Cannabis evidence is limited for disease modification but moderate for chronic-pain and sleep-disturbance symptoms common in RA.
- 15 states
- QUALIFYING IN
- Limited
- EVIDENCE
- M06.9
- ICD-10
Reviewed by Laura H. Meyer
Qualifying states
What it is
Rheumatoid arthritis (RA) is a chronic autoimmune disease in which the body's immune system attacks the synovium (the membrane lining the joints), causing inflammation, pain, swelling, stiffness, and progressive joint damage. RA typically affects the small joints of the hands and feet symmetrically, often with morning stiffness lasting more than an hour. Untreated, RA can cause permanent joint deformity, bone erosion, and significant disability. Extra-articular manifestations include rheumatoid nodules, interstitial lung disease, vasculitis, and accelerated cardiovascular disease.
Cannabis and cannabis-derived therapies
Cannabis is not a disease-modifying treatment for rheumatoid arthritis. Disease modification (slowing or halting joint damage) requires DMARDs and biologics under rheumatologist supervision. The 2017 NASEM consensus report did not identify high-tier evidence for cannabis as a treatment for RA disease activity.
Cannabis evidence is stronger for RA-related symptoms:
- Chronic pain: the NASEM substantial-evidence finding for chronic pain in adults applies to RA-related pain.
- Sleep disturbance: moderate evidence supports cannabis use for sleep problems, which are common in RA.
- Mood symptoms: anxiety and depression often co-occur with RA; cannabis effects on these are mixed in the literature.
Preclinical data on cannabinoid effects in animal models of arthritis (CB2-receptor-mediated anti-inflammatory effects) has not translated to consistent clinical benefit in RA patients.
Practical considerations
Cannabis should be used adjunctively rather than as a substitute for DMARD or biologic therapy. Patients should coordinate cannabis use with their rheumatologist, particularly when also taking methotrexate, JAK inhibitors, or biologics (potential immune-modulatory interactions are incompletely characterized).
Drug interactions include additive CNS depression with opioids, gabapentinoids, and benzodiazepines. Cannabis-induced tachycardia may complicate cardiovascular risk in patients with RA-associated atherosclerosis. Smoked cannabis is contraindicated in patients with RA-associated interstitial lung disease.
Important: RA is a progressive disease that requires early and aggressive disease-modifying treatment to prevent joint damage. Patients should not substitute cannabis for prescribed DMARDs or biologics. The cannabis benefit in RA is symptom management, not disease control.
Frequently asked questions
How strong is the cannabis evidence for rheumatoid arthritis?
Limited at the disease level, moderate at the symptom level. The 2017 NASEM consensus report did not identify high-tier evidence for cannabis as a treatment for RA disease activity. The chronic-pain finding (substantial evidence) does apply to RA-related pain. Sleep disturbance, common in RA, also has moderate evidence support. Cannabis is not a disease-modifying anti-rheumatic drug (DMARD) and should not substitute for one.
Is any cannabis-derived product FDA-approved for RA?
No. No cannabis or cannabinoid product is FDA-approved for rheumatoid arthritis. Standard care uses DMARDs (methotrexate, hydroxychloroquine, sulfasalazine, leflunomide), biologics (TNF inhibitors, JAK inhibitors, IL-6 inhibitors), and NSAIDs or low-dose corticosteroids for symptom management.
Which RA-related symptoms have the most cannabis-related evidence?
Chronic pain and sleep disturbance have the most NASEM-recognized evidence. Patient-reported anxiety, depression, and morning stiffness reduction are common in observational data but less rigorously studied. Cannabis effects on inflammatory markers (CRP, ESR, RF) have not been consistently demonstrated in clinical trials.
Which states qualify rheumatoid arthritis for medical cannabis?
Several states explicitly list rheumatoid arthritis as a qualifying condition (Connecticut, Michigan, and others). Practitioner-discretion states (Oklahoma, New York post-2022, Missouri, Virginia post-2023) can certify for RA. States that recognize severe chronic pain or severe arthritis often capture RA within those broader categories.
Sources
- NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 16, 2026
- American College of Rheumatology: Cannabis & Rheumatic Diseasesaccessed May 16, 2026